Drugs / Hu1928-Hu20BB
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04160195 | Dec 2019 → Jun 2021 | chronic lymphocytic leukemia/small lymphocytic lymphoma | National Cancer Institute (NCI) | Terminated | No outcome recorded Stop: Enrollment |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Hu1928-Hu20BB | “T cells expressing this CAR construct, called Hu1928-Hu20BB, can specifically recognize CD19 and CD20-expressing target cells in vitro and eradicate CD19 or CD20-expressing...” NCT04160195 ↗ |
| Action | Deplete | “Researchers think that a person's T cells can be modified in a lab to kill cells that have CD19 and CD20 on the surface.” NCT04160195 ↗ |
| Modality | Cell therapy | “T-cells obtained by leukapheresis will be genetically modified to express the Hu1928-Hu20BB CAR construct.” NCT04160195 ↗ |
| Route | Intravenous | “Participants will receive the T cells through a vein.” NCT04160195 ↗ |
| Target | CD19 | “T cells expressing this CAR construct, called Hu1928-Hu20BB, can specifically recognize CD19 and CD20-expressing target cells in vitro and eradicate CD19 or CD20-expressing...” NCT04160195 ↗ |